Volume 5, Number 3—June 1999
The Cost Effectiveness of Vaccinating against Lyme Disease
|Item||Cost/year ($)||Length of treatment||Total costsa ($)|
|Case resolved: no sequelae|
|Office visits (2)||50|
|5 hrs lost work time||62|
|Sequelaeb due to early and late disseminated disease|
|Cardiac-total||6,845||< 1 yr||6,845|
aAll costs that occur over more than 1 year are discounted at a rate of 3% per year.
bSee text for description of the sequelae.
cDirect costs are for all medical costs and are derived from the 1-year charges reported by Magid et al. (29), inflated to 1996 dollars (factor of 1.528) (40), and then adjusted by a cost-to-charge ratio of 0.53 (43) (see text for details).
dIndirect costs are the valuation of lost productivity due to Lyme disease-related illness, with each day lost valued at $100. For cardiac-related sequelae, it was assumed that 14 workdays were lost, and for neurologic and arthritic-related sequelae, it was assumed that 21 workdays were lost each year.
- Page created: December 10, 2010
- Page last updated: December 10, 2010
- Page last reviewed: December 10, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)